The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment of relapsed/refractory multiple myeloma with weekly cyclophosphamide plus bortezomib plus prednisone or dexamethasone (CyBor-P/D): Updated experience at Princess Margaret Cancer Centre (PMCC).
Donna Ellen Reece
Consultant or Advisory Role - Janssen-Ortho
Honoraria - Janssen-Ortho
Research Funding - Janssen-Ortho; Millennium
Young Trieu
No relevant relationships to disclose
Esther Masih-Khan
No relevant relationships to disclose
Christine Chen
No relevant relationships to disclose
Vishal Kukreti
No relevant relationships to disclose
Giovanni Piza Rodriguez
No relevant relationships to disclose
Rodger Edwin Tiedemann
Honoraria - Janssen-Ortho
Suzanne Trudel
No relevant relationships to disclose